1
|
Catalán Ú, Pedret A, Yuste S, Rubió L, Piñol C, Sandoval-Ramírez BA, Companys J, Foguet E, Herrero P, Canela N, Motilva MJ, Solà R. Red-Fleshed Apples Rich in Anthocyanins and White-Fleshed Apples Modulate the Aorta and Heart Proteome in Hypercholesterolaemic Rats: The AppleCOR Study. Nutrients 2022; 14:nu14051047. [PMID: 35268023 PMCID: PMC8912372 DOI: 10.3390/nu14051047] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/13/2022] [Revised: 02/21/2022] [Accepted: 02/24/2022] [Indexed: 01/27/2023] Open
Abstract
The impact of a red-fleshed apple (RFA) rich in anthocyanins (ACNs), a white-fleshed apple (WFA) without ACNs, and an extract infusion from Aronia fruit (AI) equivalent in dose of cyanidin-3-O-galactoside (main ACN) as RFA was determined by the proteome profile of aorta and heart as key cardiovascular tissues. Hypercholesterolaemic Wistar rats were separated into six groups (n = 6/group; three males and three females) and the proteomic profiles were analyzed using nanoliquid chromatography coupled to mass spectrometry. No adverse events were reported and all products were well tolerated. RFA downregulated C1QB and CFP in aorta and CRP in heart. WFA downregulated C1QB and CFP in aorta and C9 and C3 in aorta and heart, among other proteins. AI downregulated PRKACA, IQGAP1, and HSP90AB1 related to cellular signaling. Thus, both apples showed an anti-inflammatory effect through the complement system, while RFA reduced CRP. Regardless of the ACN content, an apple matrix effect was observed that involved different bioactive components, and inflammatory proteins were reduced.
Collapse
Affiliation(s)
- Úrsula Catalán
- Functional Nutrition, Oxidation, and CVD Research Group (NFOC-Salut), Medicine and Surgery Department, Faculty of Medicine and Health Sciences, Universitat Rovira i Virgili, 43201 Reus, Spain; (Ú.C.); (B.A.S.-R.); (R.S.)
- Institut d’Investigació Sanitària Pere Virgili (IISPV), 43204 Reus, Spain
- Unitat de Nutrició i Salut, Eurecat, Centre Tecnològic de Catalunya, 43204 Reus, Spain;
| | - Anna Pedret
- Functional Nutrition, Oxidation, and CVD Research Group (NFOC-Salut), Medicine and Surgery Department, Faculty of Medicine and Health Sciences, Universitat Rovira i Virgili, 43201 Reus, Spain; (Ú.C.); (B.A.S.-R.); (R.S.)
- Unitat de Nutrició i Salut, Eurecat, Centre Tecnològic de Catalunya, 43204 Reus, Spain;
- Correspondence: ; Tel.: +34-977-75-9375
| | - Silvia Yuste
- Food Technology Department, Universitat de Lleida-AGROTECNIO Center, 25198 Lleida, Spain; (S.Y.); (L.R.)
| | - Laura Rubió
- Food Technology Department, Universitat de Lleida-AGROTECNIO Center, 25198 Lleida, Spain; (S.Y.); (L.R.)
| | - Carme Piñol
- Department of Medicine, Universitat de Lleida, 25008 Lleida, Spain;
- Institut de Recerca Biomèdica de Lleida, Fundació Dr. Pifarré-IRBLleida, 25198 Lleida, Spain
| | - Berner Andrée Sandoval-Ramírez
- Functional Nutrition, Oxidation, and CVD Research Group (NFOC-Salut), Medicine and Surgery Department, Faculty of Medicine and Health Sciences, Universitat Rovira i Virgili, 43201 Reus, Spain; (Ú.C.); (B.A.S.-R.); (R.S.)
| | - Judit Companys
- Unitat de Nutrició i Salut, Eurecat, Centre Tecnològic de Catalunya, 43204 Reus, Spain;
| | - Elisabet Foguet
- Eurecat, Centre Tecnològic de Catalunya, Centre for Omic Sciences (COS), Joint Unit Universitat Rovira i Virgili-EURECAT, 43204 Reus, Spain; (E.F.); (P.H.); (N.C.)
| | - Pol Herrero
- Eurecat, Centre Tecnològic de Catalunya, Centre for Omic Sciences (COS), Joint Unit Universitat Rovira i Virgili-EURECAT, 43204 Reus, Spain; (E.F.); (P.H.); (N.C.)
| | - Núria Canela
- Eurecat, Centre Tecnològic de Catalunya, Centre for Omic Sciences (COS), Joint Unit Universitat Rovira i Virgili-EURECAT, 43204 Reus, Spain; (E.F.); (P.H.); (N.C.)
| | - Maria-Jose Motilva
- Instituto de Ciencias de la Vid y del Vino (ICVV), Gobierno de La Rioja, CSIC, Universidad de La Rioja, 26007 Logroño, Spain;
| | - Rosa Solà
- Functional Nutrition, Oxidation, and CVD Research Group (NFOC-Salut), Medicine and Surgery Department, Faculty of Medicine and Health Sciences, Universitat Rovira i Virgili, 43201 Reus, Spain; (Ú.C.); (B.A.S.-R.); (R.S.)
- Unitat de Nutrició i Salut, Eurecat, Centre Tecnològic de Catalunya, 43204 Reus, Spain;
- Hospital Universitari Sant Joan de Reus (HUSJR), 43204 Reus, Spain
| |
Collapse
|
2
|
Pedret A, Catalán Ú, Rubió L, Baiges I, Herrero P, Piñol C, Rodríguez-Calvo R, Canela N, Fernández-Castillejo S, Motilva MJ, Solà R. Phosphoproteomic Analysis and Protein-Protein Interaction of Rat Aorta GJA1 and Rat Heart FKBP1A after Secoiridoid Consumption from Virgin Olive Oil: A Functional Proteomic Approach. J Agric Food Chem 2021; 69:1536-1554. [PMID: 33502189 DOI: 10.1021/acs.jafc.0c07164] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/12/2023]
Abstract
Protein functional interactions could explain the biological response of secoiridoids (SECs), main phenolic compounds in virgin olive oil (VOO). The aim was to assess protein-protein interactions (PPIs) of the aorta gap junction alpha-1 (GJA1) and the heart peptidyl-prolyl cis-trans isomerase (FKBP1A), plus the phosphorylated heart proteome, to describe new molecular pathways in the cardiovascular system in rats using nanoliquid chromatography coupled with mass spectrometry. PPIs modified by SECs and associated with GJA1 in aorta rat tissue were calpain, TUBA1A, and HSPB1. Those associated with FKBP1A in rat heart tissue included SUCLG1, HSPE1, and TNNI3. In the heart, SECs modulated the phosphoproteome through the main canonical pathways PI3K/mTOR signaling (AKT1S1 and GAB2) and gap junction signaling (GAB2 and GJA1). PPIs associated with GJA1 and with FKBP1A, the phosphorylation of GAB2, and the dephosphorylation of GJA1 and AKT1S1 in rat tissues are promising protein targets promoting cardiovascular protection to explain the health benefits of VOO.
Collapse
Affiliation(s)
- Anna Pedret
- Faculty of Medicine and Health Sciences, Medicine and Surgery Department, Functional Nutrition, Oxidation, and CVD Research Group (NFOC-Salut), Universitat Rovira i Virgili, Reus 43201, Spain
- Eurecat, Centre Tecnològic de Catalunya, Unitat de Nutrició i Salut, Reus 43204, Spain
| | - Úrsula Catalán
- Faculty of Medicine and Health Sciences, Medicine and Surgery Department, Functional Nutrition, Oxidation, and CVD Research Group (NFOC-Salut), Universitat Rovira i Virgili, Reus 43201, Spain
- Eurecat, Centre Tecnològic de Catalunya, Unitat de Nutrició i Salut, Reus 43204, Spain
- Institut d'Investigació Sanitària Pere Virgili (IISPV), Reus 43204, Spain
| | - Laura Rubió
- Faculty of Medicine and Health Sciences, Medicine and Surgery Department, Functional Nutrition, Oxidation, and CVD Research Group (NFOC-Salut), Universitat Rovira i Virgili, Reus 43201, Spain
- Food Technology Department, Universitat de Lleida-AGROTECNIO Center, Lleida 25198, Spain
| | - Isabel Baiges
- Eurecat, Centre Tecnològic de Catalunya, Centre for Omic Sciences (COS), Joint Unit Universitat Rovira i Virgili-EURECAT, Reus 43204, Spain
| | - Pol Herrero
- Eurecat, Centre Tecnològic de Catalunya, Centre for Omic Sciences (COS), Joint Unit Universitat Rovira i Virgili-EURECAT, Reus 43204, Spain
| | - Carme Piñol
- Department of Medicine, Universitat de Lleida, Lleida 25008, Catalonia, Spain
- Institut de Recerca Biomèdica de Lleida Fundació Dr. Pifarré-IRBLLeida, Lleida 25198, Spain
| | - Ricardo Rodríguez-Calvo
- Institut d'Investigació Sanitària Pere Virgili (IISPV), Reus 43204, Spain
- Research Unit on Lipids and Atherosclerosis, Vascular Medicine and Metabolism Unit, Universitat Rovira i Virgili, Reus 43204, Spain
- Spanish Biomedical Research Centre in Diabetes and Associated Metabolic Disorders (CIBERDEM), Institute of Health Carlos III, Madrid 28029, Spain
- Hospital Universitari Sant Joan de Reus (HUSJR), Reus 43204, Spain
| | - Núria Canela
- Eurecat, Centre Tecnològic de Catalunya, Centre for Omic Sciences (COS), Joint Unit Universitat Rovira i Virgili-EURECAT, Reus 43204, Spain
| | - Sara Fernández-Castillejo
- Faculty of Medicine and Health Sciences, Medicine and Surgery Department, Functional Nutrition, Oxidation, and CVD Research Group (NFOC-Salut), Universitat Rovira i Virgili, Reus 43201, Spain
- Eurecat, Centre Tecnològic de Catalunya, Unitat de Nutrició i Salut, Reus 43204, Spain
| | - Maria-Jose Motilva
- Instituto de Ciencias de la Vid y del Vino-ICVV CSIC, Gobierno de La Rioja, Universidad de La Rioja, Logroño 26006, Spain
| | - Rosa Solà
- Faculty of Medicine and Health Sciences, Medicine and Surgery Department, Functional Nutrition, Oxidation, and CVD Research Group (NFOC-Salut), Universitat Rovira i Virgili, Reus 43201, Spain
- Eurecat, Centre Tecnològic de Catalunya, Unitat de Nutrició i Salut, Reus 43204, Spain
- Hospital Universitari Sant Joan de Reus (HUSJR), Reus 43204, Spain
| |
Collapse
|
3
|
Dosil MA, Navaridas R, Mirantes C, Tarragona J, Eritja N, Felip I, Urdanibia I, Megino C, Domingo M, Santacana M, Gatius S, Piñol C, Barceló C, Maiques O, Macià A, Velasco A, Vaquero M, Matias-Guiu X, Dolcet X. Tumor suppressive function of E2F-1 on PTEN-induced serrated colorectal carcinogenesis. J Pathol 2018; 247:72-85. [DOI: 10.1002/path.5168] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/08/2018] [Revised: 08/22/2018] [Accepted: 09/04/2018] [Indexed: 12/27/2022]
Affiliation(s)
- Maria A Dosil
- Oncologic Pathology Group, Department de Ciències Mèdiques Bàsiques, Universitat de Lleida, Hospital Universitari Arnau de Vilanova; Institut de Recerca Biomèdica de Lleida, IRBLleida; Lleida Spain
- Centro de Investigación Biomédica en Red de Oncología (CIBERONC); Madrid Spain
| | - Raúl Navaridas
- Oncologic Pathology Group, Department de Ciències Mèdiques Bàsiques, Universitat de Lleida, Hospital Universitari Arnau de Vilanova; Institut de Recerca Biomèdica de Lleida, IRBLleida; Lleida Spain
| | - Cristina Mirantes
- Oncologic Pathology Group, Department de Ciències Mèdiques Bàsiques, Universitat de Lleida, Hospital Universitari Arnau de Vilanova; Institut de Recerca Biomèdica de Lleida, IRBLleida; Lleida Spain
| | - Jordi Tarragona
- Oncologic Pathology Group, Department de Ciències Mèdiques Bàsiques, Universitat de Lleida, Hospital Universitari Arnau de Vilanova; Institut de Recerca Biomèdica de Lleida, IRBLleida; Lleida Spain
- Centro de Investigación Biomédica en Red de Oncología (CIBERONC); Madrid Spain
| | - Núria Eritja
- Oncologic Pathology Group, Department de Ciències Mèdiques Bàsiques, Universitat de Lleida, Hospital Universitari Arnau de Vilanova; Institut de Recerca Biomèdica de Lleida, IRBLleida; Lleida Spain
- Centro de Investigación Biomédica en Red de Oncología (CIBERONC); Madrid Spain
| | - Isidre Felip
- Oncologic Pathology Group, Department de Ciències Mèdiques Bàsiques, Universitat de Lleida, Hospital Universitari Arnau de Vilanova; Institut de Recerca Biomèdica de Lleida, IRBLleida; Lleida Spain
| | - Izaskun Urdanibia
- Oncologic Pathology Group, Department de Ciències Mèdiques Bàsiques, Universitat de Lleida, Hospital Universitari Arnau de Vilanova; Institut de Recerca Biomèdica de Lleida, IRBLleida; Lleida Spain
| | - Cristina Megino
- Oncologic Pathology Group, Department de Ciències Mèdiques Bàsiques, Universitat de Lleida, Hospital Universitari Arnau de Vilanova; Institut de Recerca Biomèdica de Lleida, IRBLleida; Lleida Spain
| | - Mónica Domingo
- Oncologic Pathology Group, Department de Ciències Mèdiques Bàsiques, Universitat de Lleida, Hospital Universitari Arnau de Vilanova; Institut de Recerca Biomèdica de Lleida, IRBLleida; Lleida Spain
| | - Maria Santacana
- Oncologic Pathology Group, Department de Ciències Mèdiques Bàsiques, Universitat de Lleida, Hospital Universitari Arnau de Vilanova; Institut de Recerca Biomèdica de Lleida, IRBLleida; Lleida Spain
- Centro de Investigación Biomédica en Red de Oncología (CIBERONC); Madrid Spain
| | - Sònia Gatius
- Oncologic Pathology Group, Department de Ciències Mèdiques Bàsiques, Universitat de Lleida, Hospital Universitari Arnau de Vilanova; Institut de Recerca Biomèdica de Lleida, IRBLleida; Lleida Spain
- Centro de Investigación Biomédica en Red de Oncología (CIBERONC); Madrid Spain
| | - Carme Piñol
- Department de Medicina; Universitat de Lleida-Institut de Recerca Biomèdica de Lleida (IRBLleida); Lleida Spain
| | - Carla Barceló
- Oncologic Pathology Group, Department de Ciències Mèdiques Bàsiques, Universitat de Lleida, Hospital Universitari Arnau de Vilanova; Institut de Recerca Biomèdica de Lleida, IRBLleida; Lleida Spain
| | - Oscar Maiques
- Oncologic Pathology Group, Department de Ciències Mèdiques Bàsiques, Universitat de Lleida, Hospital Universitari Arnau de Vilanova; Institut de Recerca Biomèdica de Lleida, IRBLleida; Lleida Spain
| | - Anna Macià
- Oncologic Pathology Group, Department de Ciències Mèdiques Bàsiques, Universitat de Lleida, Hospital Universitari Arnau de Vilanova; Institut de Recerca Biomèdica de Lleida, IRBLleida; Lleida Spain
| | - Ana Velasco
- Department of Pathology and Molecular Genetics; Hospital Universitari Arnau de Vilanova, University of Lleida, IRBLleida; Lleida Spain
| | - Marta Vaquero
- Department of Pathology and Molecular Genetics; Hospital Universitari Arnau de Vilanova, University of Lleida, IRBLleida; Lleida Spain
| | - Xavier Matias-Guiu
- Oncologic Pathology Group, Department de Ciències Mèdiques Bàsiques, Universitat de Lleida, Hospital Universitari Arnau de Vilanova; Institut de Recerca Biomèdica de Lleida, IRBLleida; Lleida Spain
- Centro de Investigación Biomédica en Red de Oncología (CIBERONC); Madrid Spain
| | - Xavier Dolcet
- Oncologic Pathology Group, Department de Ciències Mèdiques Bàsiques, Universitat de Lleida, Hospital Universitari Arnau de Vilanova; Institut de Recerca Biomèdica de Lleida, IRBLleida; Lleida Spain
- Centro de Investigación Biomédica en Red de Oncología (CIBERONC); Madrid Spain
| |
Collapse
|
4
|
López de Las Hazas MC, Piñol C, Macià A, Motilva MJ. Hydroxytyrosol and the Colonic Metabolites Derived from Virgin Olive Oil Intake Induce Cell Cycle Arrest and Apoptosis in Colon Cancer Cells. J Agric Food Chem 2017; 65:6467-6476. [PMID: 28071050 DOI: 10.1021/acs.jafc.6b04933] [Citation(s) in RCA: 42] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/06/2023]
Abstract
After the sustained consumption of virgin olive oil (VOO), the unabsorbed native phenols (mainly hydroxytyrosol (HT)) are transformed into its catabolites in the intestine by microbials. The role of these catabolites in preventing colon cancer has not been sufficiently investigated. This work aims to study the antiproliferative and apoptotic activities in colon (Caco-2; HT-29) cancer cell lines of the main catabolites detected in human feces (phenylacetic, phenylpropionic, hydroxyphenylpropionic, and dihydroxyphenylpropionic acids and catechol), after the sustained VOO intake. Additionally, an assessment of the ability of these colonic cells to metabolize the studied compounds was performed. The results showed that HT and phenylacetic and hydroxyphenylpropionic acids produce cell cycle arrest and promote apoptosis. HT-29 cells were more sensitive to phenol treatments than Caco-2. In synthesis, the results of the present study represent a good starting point for understanding the potential apoptotic and antiproliferative effects of VOO phenolic compounds and their colonic metabolites.
Collapse
Affiliation(s)
- Maria-Carmen López de Las Hazas
- Food Technology Department, Universitat de Lleida-Agrotecnio Center, Escuela Técnica Superior de Ingeniería Agraria, Lleida , Avinguda Alcalde Rovira Roure 191, 25198 Lleida, Spain
| | - Carme Piñol
- Department of Medicine, Universitat de Lleida-Institut de Recerca Biomèdica de Lleida (IRBLleida) , Avinguda Alcalde Rovira Roure 80, 25198 Lleida, Spain
| | - Alba Macià
- Food Technology Department, Universitat de Lleida-Agrotecnio Center, Escuela Técnica Superior de Ingeniería Agraria, Lleida , Avinguda Alcalde Rovira Roure 191, 25198 Lleida, Spain
| | - Maria-José Motilva
- Food Technology Department, Universitat de Lleida-Agrotecnio Center, Escuela Técnica Superior de Ingeniería Agraria, Lleida , Avinguda Alcalde Rovira Roure 191, 25198 Lleida, Spain
| |
Collapse
|
5
|
de Las Hazas MCL, Motilva MJ, Piñol C, Macià A. Application of dried blood spot cards to determine olive oil phenols (hydroxytyrosol metabolites) in human blood. Talanta 2016; 159:189-193. [PMID: 27474297 DOI: 10.1016/j.talanta.2016.06.025] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/21/2016] [Revised: 06/09/2016] [Accepted: 06/14/2016] [Indexed: 11/28/2022]
Abstract
In this study, a fast and simple blood sampling and sample pre-treatment method based on the use of the dried blood spot (DBS) cards and ultra-performance liquid chromatography coupled to tandem mass spectrometry (UPLC-MS/MS) for the quantification of olive oil phenolic metabolites in human blood was developed and validated. After validation, the method was applied to determine hydroxytyrosol metabolites in human blood samples after the acute intake of an olive oil phenolic extract. Using the FTA DMPK-A DBS card under optimum conditions, with 20µL as the blood solution volume, 100µL of methanol/Milli-Q water (50/50, v/v) as the extraction solvent and 7 disks punched out from the card, the main hydroxytyrosol metabolites (hydroxytyrosol-3-O-sulphate and hydroxytyrosol acetate sulphate) were identified and quantified. The developed methodology allowed detecting and quantifying the generated metabolites at low μM levels. The proposed method is a significant improvement over existing methods to determine phenolic metabolites circulating in blood and plasma samples, thus making blood sampling possible with the volunteer pricking their own finger, and the subsequent storage of the blood in the DBS cards prior to chromatographic analysis.
Collapse
Affiliation(s)
- María Carmen López de Las Hazas
- Food Technology Department, Agrotecnio Center, Escola Tècnica Superior d'Enginyeria Agrària, University of Lleida, Avda. Alcalde Rovira Roure 191, 25198 Lleida, Spain
| | - Maria José Motilva
- Food Technology Department, Agrotecnio Center, Escola Tècnica Superior d'Enginyeria Agrària, University of Lleida, Avda. Alcalde Rovira Roure 191, 25198 Lleida, Spain
| | - Carme Piñol
- Department of Medicine, Facultat de Medicina, University of Lleida, Avda/Alcalde Rovira Roure 80, 25198 Lleida, Spain
| | - Alba Macià
- Food Technology Department, Agrotecnio Center, Escola Tècnica Superior d'Enginyeria Agrària, University of Lleida, Avda. Alcalde Rovira Roure 191, 25198 Lleida, Spain.
| |
Collapse
|
6
|
Piñol C. Análisis de coste-efectividad del interferón beta-1b en el tratamiento de pacientes con síndrome desmielinizante aislado indicativo de esclerosis múltiple en España. Neurologia 2016; 31:247-54. [DOI: 10.1016/j.nrl.2015.03.014] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/23/2014] [Revised: 01/09/2015] [Accepted: 03/05/2015] [Indexed: 10/23/2022] Open
|
7
|
Eritja N, Arjó G, Santacana M, Gatius S, Ramírez-Núñez O, Arcal L, Serrano JCE, Pamplona R, Dolcet X, Piñol C, Christou P, Matias-Guiu X, Portero-Otin M. Oral intake of genetically engineered high-carotenoid corn ameliorates hepatomegaly and hepatic steatosis in PTEN haploinsufficient mice. Biochim Biophys Acta Mol Basis Dis 2016; 1862:526-535. [PMID: 26820774 DOI: 10.1016/j.bbadis.2016.01.018] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/27/2015] [Revised: 01/19/2016] [Accepted: 01/24/2016] [Indexed: 01/11/2023]
Abstract
Non-alcoholic fatty liver disease (NAFLD) is the most common form of chronic liver disease. Here we show that a mouse model of haploinsufficiency in the lipid and protein phosphatase and tensin homolog protein (PTEN(+/-)) exhibits hepatomegaly, increased liver lipogenic gene expression (SREBP-1C and PPARγ) and hepatic lesions analogous to human NAFLD. The livers of PTEN(+/-) mice also contained lower levels of retinoic acid (RA) than normal, similarly to human NAFLD patients. The RA signaling pathway thus offers a novel therapeutic target for the treatment of NAFLD although the impact of nutrition in this context is unclear. We therefore fed PTEN(+/-) mice for 36weeks a diet containing genetically engineered high-carotenoid corn (HCAR) to investigate its potential beneficial effects on the hepatic symptoms of NAFLD. The HCAR diet reduced hepatomegaly and promoted the repartitioning of fatty acids in the liver, away from triacylglycerol storage. At the molecular level, the HCAR diet clearly reduced lipogenic gene expression, boosted catabolism, and increased hepatic RA levels. These results set the stage for human trials to evaluate the use of high-carotenoid foods for the reduction or prevention of steatosis in NAFLD.
Collapse
Affiliation(s)
- Nuria Eritja
- Oncologic Pathology Group, Dept. de Ciències Mèdiques Bàsiques, Universitat de Lleida, Hospital Universitari Arnau de Vilanova, Institut de Recerca Biomèdica de Lleida (IRBLleida), Lleida, Spain.
| | - Gemma Arjó
- Departament de Medicina, Universitat de Lleida-Institut de Recerca Biomèdica de Lleida (IRBLleida), Lleida, Spain
| | - Maria Santacana
- Oncologic Pathology Group, Dept. de Ciències Mèdiques Bàsiques, Universitat de Lleida, Hospital Universitari Arnau de Vilanova, Institut de Recerca Biomèdica de Lleida (IRBLleida), Lleida, Spain
| | - Sònia Gatius
- Oncologic Pathology Group, Dept. de Ciències Mèdiques Bàsiques, Universitat de Lleida, Hospital Universitari Arnau de Vilanova, Institut de Recerca Biomèdica de Lleida (IRBLleida), Lleida, Spain
| | - Omar Ramírez-Núñez
- Department of Experimental Medicine, Faculty of Medicine, University of Lleida-IRBLleida, Av. Rovira Roure 80, 25198 Lleida, Spain
| | - Laura Arcal
- Departament de Medicina, Universitat de Lleida-Institut de Recerca Biomèdica de Lleida (IRBLleida), Lleida, Spain
| | - José C E Serrano
- Department of Experimental Medicine, Faculty of Medicine, University of Lleida-IRBLleida, Av. Rovira Roure 80, 25198 Lleida, Spain
| | - Reinald Pamplona
- Department of Experimental Medicine, Faculty of Medicine, University of Lleida-IRBLleida, Av. Rovira Roure 80, 25198 Lleida, Spain
| | - Xavi Dolcet
- Oncologic Pathology Group, Dept. de Ciències Mèdiques Bàsiques, Universitat de Lleida, Hospital Universitari Arnau de Vilanova, Institut de Recerca Biomèdica de Lleida (IRBLleida), Lleida, Spain
| | - Carme Piñol
- Departament de Medicina, Universitat de Lleida-Institut de Recerca Biomèdica de Lleida (IRBLleida), Lleida, Spain
| | - Paul Christou
- Department of Plant Production and Forestry Science, School of Agrifood and Forestry Science and Engineering (ETSEA), University of Lleida-Agrotecnio Center, Lleida, Spain; Institució Catalana de Reserca i Estudis Avanc¸ats, Passeig Lluís Companys 23, 08010 Barcelona, Spain
| | - Xavier Matias-Guiu
- Oncologic Pathology Group, Dept. de Ciències Mèdiques Bàsiques, Universitat de Lleida, Hospital Universitari Arnau de Vilanova, Institut de Recerca Biomèdica de Lleida (IRBLleida), Lleida, Spain
| | - Manuel Portero-Otin
- Department of Experimental Medicine, Faculty of Medicine, University of Lleida-IRBLleida, Av. Rovira Roure 80, 25198 Lleida, Spain.
| |
Collapse
|
8
|
Rubió L, Serra A, Macià A, Piñol C, Romero MP, Motilva MJ. In vivo distribution and deconjugation of hydroxytyrosol phase II metabolites in red blood cells: A potential new target for hydroxytyrosol. J Funct Foods 2014. [DOI: 10.1016/j.jff.2014.06.001] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022] Open
|
9
|
Arjó G, Portero M, Piñol C, Viñas J, Matias-Guiu X, Capell T, Bartholomaeus A, Parrott W, Christou P. Plurality of opinion, scientific discourse and pseudoscience: an in depth analysis of the Séralini et al. study claiming that Roundup™ Ready corn or the herbicide Roundup™ cause cancer in rats. Transgenic Res 2013; 22:255-67. [PMID: 23430588 DOI: 10.1007/s11248-013-9692-9] [Citation(s) in RCA: 30] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/20/2012] [Accepted: 02/02/2013] [Indexed: 10/27/2022]
Abstract
A recent paper published in the journal Food and Chemical Toxicology presents the results of a long-term toxicity study related to a widely-used commercial herbicide (Roundup™) and a Roundup-tolerant genetically modified variety of maize, concluding that both the herbicide and the maize varieties are toxic. Here we discuss the many errors and inaccuracies in the published article resulting in highly misleading conclusions, whose publication in the scientific literature and in the wider media has caused damage to the credibility of science and researchers in the field. We and many others have criticized the study, and in particular the manner in which the experiments were planned, implemented, analyzed, interpreted and communicated. The study appeared to sweep aside all known benchmarks of scientific good practice and, more importantly, to ignore the minimal standards of scientific and ethical conduct in particular concerning the humane treatment of experimental animals.
Collapse
Affiliation(s)
- Gemma Arjó
- Departament de Medicina, Universitat de Lleida-Institut de Recerca Biomèdica de Lleida (IRBLleida), Lleida, Spain
| | | | | | | | | | | | | | | | | |
Collapse
|
10
|
Piñol C. Análisis de coste-efectividad del ácido acetilsalicílico frente al clopidogrel en prevención secundaria tras infarto agudo de miocardio. ACTA ACUST UNITED AC 2013. [DOI: 10.1007/bf03320903] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
11
|
Affiliation(s)
- J. Ruiz‐Olmo
- Government of Catalonia Ministry of Agriculture, Livestock, Fisheries, Food and Natural Environment General Directorate of Environment and Biodiversity Barcelona Spain
| | - A. Such‐Sanz
- Government of Catalonia Ministry of Agriculture, Livestock, Fisheries, Food and Natural Environment Forestal Catalana, SA Barcelona Spain
| | - C. Piñol
- Government of Catalonia Ministry of Agriculture, Livestock, Fisheries, Food and Natural Environment C.F. Vallcalent Lleida Spain
| |
Collapse
|
12
|
Arjó G, Capell T, Matias-Guiu X, Zhu C, Christou P, Piñol C. Mice fed on a diet enriched with genetically engineered multivitamin corn show no sub-acute toxic effects and no sub-chronic toxicity. Plant Biotechnol J 2012; 10:1026-1034. [PMID: 22928600 DOI: 10.1111/j.1467-7652.2012.00730.x] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/01/2023]
Abstract
Multivitamin corn is a novel genetically engineered variety that simultaneously produces high levels of β-carotene, ascorbate and folate, and therefore has the potential to address simultaneously multiple micronutrient deficiencies caused by the lack of vitamins A, B9 and C in developing country populations. As part of the development process for genetically engineered crops and following European Food Safety Authority (EFSA) recommendations, multivitamin corn must be tested in whole food/feed sub-chronic animal feeding studies to ensure there are no adverse effects, and potential allergens must be identified. We carried out a 28-day toxicity assessment in mice, which showed no short-term sub-acute evidence of diet-related adverse health effects and no difference in clinical markers (food consumption, body weight, organ/tissue weight, haematological and biochemical blood parameters and histopathology) compared to mice fed on a control diet. A subsequent 90-day sub-chronic feeding study again showed no indications of toxicity compared to mice fed on control diets. Our data confirm that diets enriched with multivitamin corn have no adverse effects on mice, do not induce any clinical signs of toxicity and do not contain known allergens.
Collapse
Affiliation(s)
- Gemma Arjó
- Departament de Medicina, Universitat de Lleida-Institut de Recerca Biomèdica de Lleida, Lleida, Spain
| | | | | | | | | | | |
Collapse
|
13
|
Abstract
AIM The aim of this study was to determine whether telomere length is an independent prognostic factor for the prevention and survival of colorectal cancer. METHOD Terminal restriction fragment (TRF) length was determined by Southern blot in tumours and paired normal tissue samples from 147 patients with sporadic colorectal cancer who had undergone surgery. The TRF length ratio (TRFLR) was determined as the ratio between the length of the patient's tumour and normal tissue.The classification and regression tree technique was used to determine optimal cut-off values (≤ 1 or > 1). RESULTS Mean TRF length was 6.79 Kbp (1.19-13.99) in tumour tissue and 7.81 Kbp (3.63-15.70) in normal mucosa (P < 0.001). Mean TRFLR was 0.88. Telomere length and telomere length ratio were not correlated with any clinicopathological factors. In univariate analysis, overall survival was related to N stage (lymph node +/-; P = 0.002), TNM classification (P = 0.019) and TRFLR (≤ 1 or > 1; P = 0.014). In multivariate analysis, overall survival was significantly associated with TRFLR and N stage. Colorectal cancer patients with TRFLR ≤ 1 and negative lymph node involvement had a higher overall survival rate. CONCLUSION Telomere length ratio is an independent prognostic factor for survival in colorectal cancer patients, and the telomere lengths in the normal and tumour mucosa of the same patient present with parallel behaviour.
Collapse
Affiliation(s)
- C Valls
- Department of Medicine, Medical School, Lleida, Lleida, Spain
| | | | | | | | | |
Collapse
|
14
|
Piñol C, Alegría E, Langham S. Carga epidemiológica y económica de la hipertensión arterial en pacientes con síndrome metabólico en España: un modelo basado en la prevalencia. Hipertensión y Riesgo Vascular 2011. [DOI: 10.1016/j.hipert.2011.05.004] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
|
15
|
Gonzalo V, Petit A, Castellví-Bel S, Pellisé M, Muñoz J, Piñol C, Rodríguez-Moranta F, Clofent J, Balaguer F, Giráldez MD, Ocaña T, Serradesanferm A, Grau J, Reñé JM, Panés J, Castells A. Telomerase mRNA expression and immunohistochemical detection as a biomarker of malignant transformation in patients with inflammatory bowel disease. Gastroenterología y Hepatología 2010; 33:288-96. [DOI: 10.1016/j.gastrohep.2009.12.011] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Received: 11/03/2009] [Revised: 12/23/2009] [Accepted: 12/23/2009] [Indexed: 12/25/2022]
|
16
|
Marqués P, Martín D, Piñol C, Ladron de Cegama U. P01-227 - Therapeutic interventions in behavioural symptoms characteristic of eating disorders. Eur Psychiatry 2010. [DOI: 10.1016/s0924-9338(10)70433-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/19/2022] Open
|
17
|
Marqués P, Ladrón de Cegama U, Martinez V, Valera C, Piñol C. P03-355 Antidepressants risks adverse hematological effects. Eur Psychiatry 2010. [DOI: 10.1016/s0924-9338(10)70961-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/19/2022] Open
|
18
|
Delgado J, Febrer L, Nieves D, Piñol C, Brosa M. [Cost-reduction analysis for oral versus intravenous fludarabine (Beneflur) in Spain]. Farm Hosp 2009; 33:240-246. [PMID: 19775574] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/28/2023] Open
Abstract
INTRODUCTION Various international studies have shown that fludarabine is effective, safe, and efficient for treating B-cell chronic lymphocytic leukemia (B-CLL). The purpose of the present study was to carry out a cost-minimization analysis for two alternative forms of fludarabine (oral and intravenous) used to treat B-CLL in Spain. METHODS The presence of clinical evidence about the treatment equivalence of the two options being compared (oral fludarabine vs. intravenous fludarabine) led us to carry out a cost-minimization analysis. A pharmacoeconomic model was constructed to compile data from the literature and experts' opinions in order to determine the use of health resources associated with the treatment; unit costs were obtained from Spanish databases. The analysis contemplated two perspectives: that of the national health service, which includes only direct health costs, and the social perspective, which also includes the indirect costs that result from loss of productivity. RESULTS Although fludarabine in its oral form has a higher purchase price than generic intravenous fludarabine does, increased administration costs for the latter, which is used in hospitals, mean that oral fludarabine use produces total savings of euro1,908 and euro1,292 for single-drug therapy and combined therapy with cyclophosphamide, respectively. Including indirect costs increased the savings associated with the oral form of the drug. CONCLUSIONS In B-CLL patients, treatment with oral fludarabine has a lower cost than treatment with intravenous fludarabine, in both single-drug therapy and combined therapy. Various sensitivity analyses confirmed these results and showed that oral fludarabine should be the treatment of choice for B-CLL in Spain, unless contrain.
Collapse
MESH Headings
- Administration, Oral
- Antimetabolites, Antineoplastic/administration & dosage
- Antimetabolites, Antineoplastic/economics
- Costs and Cost Analysis
- Humans
- Injections, Intravenous
- Leukemia, Lymphocytic, Chronic, B-Cell/drug therapy
- Leukemia, Lymphocytic, Chronic, B-Cell/economics
- Spain
- Vidarabine Phosphate/administration & dosage
- Vidarabine Phosphate/analogs & derivatives
- Vidarabine Phosphate/economics
Collapse
Affiliation(s)
- Julio Delgado
- Hospital de la Santa Creu i Sant Pau, Barcelona, España
| | | | | | | | | |
Collapse
|
19
|
Delgado J, Febrer L, Nieves D, Piñol C, Brosa M. Análisis de minimización de costes de fludarabina (Beneflur®) oral vs. vía intravenosa en España. Farmacia Hospitalaria 2009. [DOI: 10.1016/s1130-6343(09)72463-8] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
20
|
Piñol C, Roze S, Valentine W, Evers T. [Cost-effectiveness of the addition of acarbose to the treatment of patients with type-2 diabetes in Spain]. Gac Sanit 2007; 21:97-104; discussion 105. [PMID: 17419924 DOI: 10.1157/13101034] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/06/2023]
Abstract
OBJECTIVES To assess the cost-effectiveness of the addition of acarbose to existing treatment in patients with type 2 diabetes mellitus (DM2) in Spain. METHODS The CORE Diabetes Model (a published and validated computer simulation model) was used to project long-term clinical and cost outcomes in DM2. Transition probabilities and risk adjustments were derived from published sources. Treatment effects and baseline cohort characteristics were based on a meta-analysis. Direct costs were retrieved from published sources and projected over patient lifetimes from the perspective of the Spanish National Health Service. Costs and clinical benefits were discounted at 3% per year. Sensitivity analyses were performed. RESULTS Acarbose treatment was associated with improved life expectancy (0.23 years) and quality-adjusted life years (QALY) (0.21 years). Direct costs were on average euro 468 per patient more expensive with acarbose than with placebo. The incremental cost-effectiveness ratios were euro 2,002 per life year gained and euro 2,199 per QALY gained. An acceptability curve showed that with a willingness to pay euro 20,000, which is generally accepted to represent very good value for money, acarbose treatment was associated with a 93.5% probability of being cost-effective. CONCLUSIONS This long-term economic study showed that the addition of acarbose to existing therapy for DM2 was associated with improvements in life expectancy and QALYs in these patients.
Collapse
Affiliation(s)
- Carme Piñol
- Química Farmacéutica Bayer, S. A., Barcelona, España.
| | | | | | | |
Collapse
|
21
|
Silvestre-Ferreira AC, Marco I, Daussa B, Piñol C, Lavin S, Pastor J. Blood group system in a captive population of European wildcats (Felis silvestris). Vet Rec 2006; 159:567-8. [PMID: 17056656 DOI: 10.1136/vr.159.17.567] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Affiliation(s)
- A C Silvestre-Ferreira
- Department of Veterinary Sciences, Veterinary Hospital, University of Trás-os-Montes e Alto Douro, 5001-911 Vila Real, Portugal
| | | | | | | | | | | |
Collapse
|
22
|
Lamotte M, Piñol C, Brotons C, Annemans L, Guardiola E, Evers T, Kubin M. Evaluación económica del tratamiento con ácido acetilsalicílico en dosis bajas en la prevención primaria de enfermedades cardiovasculares. Rev Esp Cardiol 2006. [DOI: 10.1157/13091885] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
|
23
|
Lamotte M, Piñol C, Brotons C, Annemans L, Guardiola E, Evers T, Kubin M. [Health economic evaluation of low-dose acetylsalicylic acid in the primary prevention of cardiovascular disease]. Rev Esp Cardiol 2006; 59:807-15. [PMID: 16938230] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/11/2023]
Abstract
INTRODUCTION AND OBJECTIVES Low-dose aspirin is standard treatment for patients with a history of cardiovascular disease. Its use in primary prevention is more controversial. However, recent studies also support the use of aspirin in high-risk individuals with no history of cardiovascular disease. This study investigated the health economic implications of using low-dose aspirin in the primary prevention of cardiovascular disease in Spain. METHODS A model was developed to predict the cost-effectiveness of low-dose aspirin in the primary prevention of cardiovascular disease over a period of 10 years. The direct costs used were those of the Spanish National Health Service (NHS). Results were expressed as cost per life-year gained and per quality-adjusted life-year gained. RESULTS Administering low-dose aspirin to an individual with a 10-year risk of coronary heart disease > or =15% resulted in an average net saving of e 797 (95% CI, e 263-1331) over the 10-year period, with savings starting in the first year. For an annual risk > or =0.24%, this form of treatment would reduce NHS costs. Treating all at-risk individuals in the Spanish population with aspirin would save e 26.5 million from the healthcare budget, starting in the first year. CONCLUSIONS Administering low-dose aspirin to individuals with a 10-year risk of coronary heart disease > or =15% would result in significant cost savings for the Spanish NHS. Sensitivity analysis confirmed the robustness of these findings.
Collapse
Affiliation(s)
- Mark Lamotte
- Health Economics and Disease Management Unit. IMS Health. Bruselas. Bélgica
| | | | | | | | | | | | | |
Collapse
|
24
|
Piñol C. Evaluación económica del tratamiento con ácido acetilsalicílico más esomeprazol comparado con clopidogrel en la prevención de la hemorragia gastrointestinal. Gaceta Sanitaria 2006; 20:54-7. [PMID: 16539994 DOI: 10.1157/13084128] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/05/2023]
Abstract
OBJECTIVE To evaluate the use of aspirin plus esomeprazole vs. clopidogrel in the prevention of gastrointestinal bleeding. METHODS We performed a cost-effectiveness analysis (two-branch decision tree: aspirin plus esomeprazole or clopidogrel) of prevention of gastrointestinal bleeding over a 2-year period, as well as sensitivity analyses. RESULTS The total cost of aspirin plus esomeprazole treatment (2,865 Euro/patient free of hemorrhage) was lower than that of clopidogrel (2,965 Euro). Aspirin treatment was dominant. The combination continued to be dominant in all sensitivity analyses. When esomeprazole 40 mg was substituted by omeprazole 40 mg, the cost of combination therapy decreased to 1,934 Euro/prevented hemorrhage. CONCLUSIONS The association of esomeprazole and aspirin is more cost-effective than clopidogrel in preventing gastrointestinal bleeding. Aspirin plus omeprazole was even more cost-effective.
Collapse
Affiliation(s)
- Carme Piñol
- Unidad de Farmacoeconomía y Relaciones Institucionales, Departamento de Investigación y Desarrollo, Química Farmacéutica Bayer, S.A., Barcelona, España.
| |
Collapse
|
25
|
Le Lamer S, Cros G, Serrano JJ, Piñol C, Fernändez-Alvarez J, Bressolle F. Estimation of pharmacokinetic parameters of sodium tungstate after multiple-dose during preclinical studies in beagle dogs. Eur J Pharm Sci 2001; 14:323-9. [PMID: 11684407 DOI: 10.1016/s0928-0987(01)00185-3] [Citation(s) in RCA: 16] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
Abstract
In this paper, an empirical Bayes methodology was used to determine the pharmacokinetic profile of sodium tungstate in beagle dogs after multiple oral dosing using the P-PHARM computer program. The population estimation algorithm used in P-PHARM is an EM-type procedure. Sodium tungstate was administered orally, three times a day, (i) for 11 days (21 and 42 mg/kg per day) to 18 dogs (nine males and nine females) and (ii) for 13 weeks (15, 30 and 60 mg/kg per day) to 28 dogs (14 males, 14 females). Six other dogs received the compound intravenously (25 and 50 mg/kg). Plasma concentration profiles versus time were compatible with a two-compartment model and first-order kinetics. After oral administration, F (0.61+/-0.086 vs. 0.48+/-0.093), and normalized (to a 7-mg/kg dose of sodium tungstate) AUC (54+/-8.4 vs. 41.2+/-8.5 mg/l x h), C(max) (10.6+/-0.49 vs. 8.5+/-0.57 microg/ml) and C(min) (3.04+/-0.23 vs. 2.04+/-0.22 microg/ml), were higher in male than in female dogs. However, the introduction of the gender in the final model did not contribute statistically to an improvement of the fit of the population pharmacokinetic model. In males, t(1/2) elimination averaged 3.1+/-0.56 vs. 2.6+/-0.18 h in females. The duration of treatment did not modify statistically the pharmacokinetic parameters. After repeated multiple oral administration of 15-60 mg/kg per day of sodium tungstate, tungsten plasma concentrations increased in proportion to dose. No dose-dependent changes in pharmacokinetic parameters occurred.
Collapse
Affiliation(s)
- S Le Lamer
- Clinical Pharmacokinetic Laboratory, Faculty of Pharmacy, B.P. 14491, 34093 Montpellier Cedex 5, France
| | | | | | | | | | | |
Collapse
|
26
|
Viñas-Salas J, Villalba-Acosta J, Scaramucci M, Rodas JH, Rodríguez G, Tiziana Ciutto S, Torres S, Fermiñan A, Pelayo A, Piñol C. Complications of colonic diverticular disease. Comparative study of two series. Rev Esp Enferm Dig 2001; 93:649-58. [PMID: 11767489] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/23/2023]
Abstract
OBJECTIVE To compare the form of presentation and management of the disease in two surgical units covering geographically different populations. DESIGN Observational retrospective study. PATIENTS AND METHOD 203 cases from the 2nd Chair of Surgery of the Hospital Universitario de Clínicas de Asunción, Paraguay and 150 cases from the Hospital Universitario de Lleida, Spain. We analyzed the cause of admission, medical history, treatment and post-operative morbidity and mortality. RESULTS Paraguay series: average age: 53 years (range 34-84) for men and 62 years (range 36-92) for women. Fifty-five per cent were hospitalized because of hemorrhagic complications and 45% because of acute diverticulitis. Medical treatment was provided in 109 cases and surgery in 110, 72 of which were emergencies and 38 elective procedures (p < 0.05). Morbidity was 31.8% (40.2% in emergencies and 16% in elective procedures, p < 0.05) and mortality was 15.5% (20.2% in emergencies and 2.6% in elective procedures, p < 0.003). LLEIDA SERIES: Average age: 65.5 years (range 38-85, p < 0.01) for men and 71.4 years (range 30-93, p < 0.01) for women. Eighty-six per cent were hospitalized because of acute diverticulitis and 10.7% because of acute hemorrhage (p < 0.001). Sixteen per cent have had previous attacks (p < 0.001). Medical treatment was provided to 111 patients and surgery to 39 (p < 0.001), 33 of which were emergencies and 6 elective procedures (p < 0.04). Morbidity was 41% and mortality 12.8% (5 cases), all of which were emergencies. The surgical technique was similar in both groups: resection with primary anastomosis in elective procedures and Hartmann's procedure in most emergencies, with a rate of immediate anastomosis of 33 and 21%, respectively. CONCLUSIONS Factors related to nutrition and quality of life may influence the development of diverticular disease. Emergency surgery should be prevented. Surgeons must adapt their surgical approach to the socioeconomic and cultural medium of the population.
Collapse
Affiliation(s)
- J Viñas-Salas
- Hospital Universitario Arnau de Vilanova, Universidad de Lleida, Spain.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
27
|
Gomez L, Egido R, Guarino G, Perez L, Piñol C. [Histologic study of experimental spleen transplant in rats]. MINERVA CHIR 2000; 55:741-4. [PMID: 11265146] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/19/2023]
Abstract
BACKGROUND The objective of this paper was to demonstrate that the grafts of cervical splenic transplantation on rats using our experimental model present a normal histological appearance. METHODS Isogenic consanguineous Lewis rats 12 weeks old and weighing 250 gr. were used. Histological findings of a group of 25 cervical splenic grafts transplanted by means of splinting vascular venous microanastomoses and a group of 25 splenic grafts autotransplanted in the omentum were compared with a control group. The specimens were assigned according to a score of 0 to 4, following Moore's histological criteria. RESULTS All grafts in transplanted and autotransplanted groups had a score of 3 or 4. Then, all splenic grafts from the transplanted group had histological findings very similar to a normal spleen. In the autotransplantation group, the percentage of grafts with a score 3 (60%) was superior to the transplantation group (46%). However, the transplantation group presented a percentage of score 4 (54%), superior to the autotransplantation group (40%). CONCLUSIONS In our study all grafts from the cervical spleen transplantation group had histological findings very similar to a normal spleen. The percentage of spleens with histological normality in the transplantation group was superior to the autotransplantation group. However, there was no statistical significance.
Collapse
Affiliation(s)
- L Gomez
- Unidad de Investigación, Facultad de Medicina de Lleida, Hospital Universitario Arnau de Vilanova, Lleida, Spain
| | | | | | | | | |
Collapse
|
28
|
Arija V, Piñol C, Vallés S, Salas J. Participation in a pharmacological hypolipidaemic trial does not alter participants' dietary habits. INT J VITAM NUTR RES 1998; 68:120-4. [PMID: 9580420] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Abstract
OBJECTIVE The aim of this study was to observe whether the act of participation in a well-controlled clinical trial can, co-incidentally, modify the dyslipaemic patient's adherence to his/her diet. DESIGN AND SUBJECT: Food diaries of 55 men and 51 women (aged 46.4 +/- 10.6 and 55.8 +/- 12.1 years respectively) were analyzed at the beginning and the end of the double-blind stage of treatment (12 weeks). STATISTICS Variance analysis and multi-variant analysis with repeated data by SPSS/PC statistical package. RESULTS In neither sex were there any statistically significant differences between the start and end of the study with respect to the intake of energy, proteins, total lipids, carbohydrates, saturated fatty acids, polyunsaturated fatty acids, cholesterol, fibre and alcohol. CONCLUSIONS Although in individual cases some changes in dietary awareness can occur, on a larger scale, the hypocholesterolaemic intervention trial induced no significant overall changes in the participants dietary/lifestyle patterns and, as such, augurs well for other such trials in which the effect of the therapy may sometimes be confounded by changes in the patients' life-style patterns coincidental to the act of participation in the trial.
Collapse
Affiliation(s)
- V Arija
- Human Nutrition Unit, Faculty of Medicine and Health Science, Rovira i Virgili University
| | | | | | | |
Collapse
|
29
|
Riambau V, Piñol C. [Intermittent claudication: review of a disease of growing prevalence. II. Treatment]. Med Clin (Barc) 1998; 110:220-7. [PMID: 9580403] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Affiliation(s)
- V Riambau
- Servicio de Cirugía Cardíaca y Vascular, Hospital Clínic i Provincial, Barcelona
| | | |
Collapse
|
30
|
Riambau V, Piñol C. [Intermittent claudication. Review of a disease of growing prevalence. I. Clinical aspects, etiology, epidemiology, natural history and diagnosis]. Med Clin (Barc) 1998; 110:191-7. [PMID: 9580360] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Affiliation(s)
- V Riambau
- Institut Clínic de Malalties Cardiovasculars, Hospital Clínic i Provincial, Barcelona
| | | |
Collapse
|
31
|
Costa B, Piñol C. Acarbose in ambulatory treatment of non-insulin-dependent diabetes mellitus associated to imminent sulfonylurea failure: a randomised-multicentric trial in primary health-care. Diabetes and Acarbose Research Group. Diabetes Res Clin Pract 1997; 38:33-40. [PMID: 9347244 DOI: 10.1016/s0168-8227(97)00083-1] [Citation(s) in RCA: 18] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
To assess the efficacy and safety of acarbose as an adjunct to high sulfonylurea (SU) doses in patients with imminent SU failure, a randomised, multicentric, 6 month double-blind, parallel and placebo-controlled trial was performed in primary healthcare. Entry criteria were: NIDDM patients in concomitant dietary follow-up, age > 40 year-old, more than 3 years of diagnosed diabetes, baseline HbAlc levels between 8-12% (N: 4-6%), stable body mass index < 35 kg m-2 and glibenclamide daily dose > 10 mg. After 1 month placebo run-in period all patients were randomly allocated into two groups of treatment (acarbose 100 mg t.i.d. vs placebo). HbAlc levels, the main efficacy variable, lipid profile, fasting and postprandial blood glucose levels were performed and adverse events were also recorded. A total number of 65 patients were randomised, 36 in acarbose and 29 in a placebo group. No statistical differences were found on age (60.2/61.7 year-old), BMI (28.7/27.4 kg m-2), glibenclamide dose (14.5/14.0 mg/day) and baseline HbAlc (9.0/8.8%). Acarbose-treated patients significantly reduced HbAlc levels (9.0/7.9 vs 8.8/8.5%; P < 0.01), based upon a marked decrease, but statistically not significant, in mean postprandial plasma glucose levels (11.9/9.6 vs 12.4/11.1 mmol l-1). No significant differences between fasting plasma glucose and lipid profile were detected. A total of 31 patients (47.7%) reported adverse events, 20 (55.5%) and 11 (37.9%) in acarbose and placebo treatment group respectively. Relationship with drug was estimated as possible or probable in 16 (44.4%) of acarbose-treated patients. None of them were excluded from study participation due to insulin requirement. Only seven patients (10.7%), six with acarbose (16.6%) and one with placebo (3.8%), withdrew the study because of the adverse events. Thus, acarbose seems to be a useful option in order to improve HbAlc levels in non-insulin-dependent diabetes mellitus with imminent sulfonylurea failure.
Collapse
Affiliation(s)
- B Costa
- Grup per a l'Estudi de la Diabetis, Catalan Institute of Health (Primary Health Care Division, Reus-Altebrat), Tarragona, Catalonia, Spain.
| | | |
Collapse
|
32
|
Piñol C, Cobos A, Cases A, Esmatges E, Soler J, Closas J, Pascual R, Planas J. Nitrendipine and enalapril in the treatment of diabetic hypertensive patients with microalbuminuria. Kidney Int Suppl 1996; 55:S85-7. [PMID: 8743519] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/01/2023]
Abstract
A trial to study the efficacy, safety and tolerability of nitrendipine and enalapril in the treatment of diabetic hypertensive patients with microalbuminuria (MA) was performed to compare the effects of both drugs in the prevention of the renal impairment. Twenty-eight valid patients [13 with nitrendipine (N) and 15 with enalapril (E) with NIDDM, hypertension (diastolic blood pressure between 90 to 114 mm Hg) and MA (urinary albumin between 30 to 300 mg/24 hr) were recruited in a double blind, randomized trial. Following a placebo run-in period of two to four weeks, all eligible patients were randomly allocated to either N or E treatment. Treatment lasted six months, with two different visits at three and six months in which blood pressure (BP), heart rate (HR), renal function and MA were measured. No statistically significant differences on BP and metabolic parameters were found between both treatment groups. The geometric mean of final glomerular filtration rate (GFR) in the N group was 34.5% higher than in the E group, while the reduction on MA was most important in the E group. Eleven patients reported adverse events (AEs) and there were four dropouts, three of them due to AEs. We conclude that both treatments are a good choice for treating diabetic hypertensive patients with early altered renal function, as they reduce BP without altering metabolic parameters, increase GFR and reduce MA with a low frequency of AEs.
Collapse
Affiliation(s)
- C Piñol
- Hospital Clínic i Provincial, Hospitals Comarcals de Catalunya, Barcelona, Spain
| | | | | | | | | | | | | | | |
Collapse
|
33
|
Piñol C, Guardiola E. Efficacy and safety of nitrendipine in the outpatient treatment of mild-to-moderate hypertension. Curr Ther Res Clin Exp 1994. [DOI: 10.1016/s0011-393x(05)80255-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
|
34
|
Viñas-Salas J, Fortuny JC, Panades J, Piñol C, Prim M, Fermiñan A, Corbella G, Calderó J, Egido R. Appearance of ear tumors in Sprague-Dawley rats treated with 1,2-dimethylhydrazine when used as a model for colonic carcinogenesis. Carcinogenesis 1992; 13:493-5. [PMID: 1547541 DOI: 10.1093/carcin/13.3.493] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022] Open
Abstract
One of the models of colon carcinogenesis in rats is produced by s.c. injections of 1,2-dimethylhydrazine (DMH). This specific colon carcinogen provokes other tumors in the rat, notably intestinal tumors. Ear tumors are just marginally mentioned in the literature. We have studied the appearance and histologic characteristics of ear tumors produced by 19 s.c. injections of 21 mg/kg of DMH in 18 Sprague-Dawley rats: 15 tumors appeared in 13 ears of 10 rats (55% of the animals). Simultaneously there were 23 colonic tumors: four (26.6%) of the tumors were carcinomas, 10 (66.6%) papillomas and one (6.6%) pseudoepitheliomatous hyperplasia. We conclude that ear tumors induced by DMH appear in 55% of the rats and that it is not possible to distinguish macroscopically in terms of size and aspect between benign and malignant lesions.
Collapse
Affiliation(s)
- J Viñas-Salas
- Department of Medicine and Surgery, Faculty of Medicine, Estudi General de Lleida, University of Barcelona, Catalonia, Spain
| | | | | | | | | | | | | | | | | |
Collapse
|